Australia Ophthalmic Devices Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

Market Overview

The Australia ophthalmic devices market combines consumable and implant sales, capital equipment and recurring service revenue. Growth comes from procedure volumes, premium lens adoption, diagnostic upgrades and the spread of myopia management, rather than from a large increase in the number of clinics. Ophthalmologists, optometrists, private hospitals and retail chains buy through local subsidiaries and distributors of global manufacturers.

Three forces shape the outlook: sustained cataract demand from older Australians, the shift of surgery towards private day facilities, and the move of optometry from correction towards disease detection with imaging and artificial intelligence support. Private health insurance policy is the main source of uncertainty.

In December 2025 the Australian Institute of Health and Welfare reported 88,000 public hospital cataract admissions. In March 2026 CooperVision launched a myopia control contact lens in Australia, and in October 2026 the Senate removed and the Health Minister reintroduced the private health rebate bill.

Key Market Trends and Insights

• Surgical volume: The Australian Institute of Health and Welfare reported in December 2025 that cataract surgery was the most common public elective procedure, with 88,000 admissions.
• Waiting time: The same December 2025 release said half of public cataract patients were admitted within 106 days, which keeps pressure on private capacity and equipment.
• Schedule fee: From 1 July 2026 the Medicare Benefits Schedule fee for standard cataract surgery stood at AUD 910.35, with a 75% government rebate.
• Rebate change: The Senate committee report of 7 October 2026 showed the rebate for people aged 70 and over falling from 32.158% to 24.118% from April 2027.

Australia Ophthalmic Devices Market Size and Forecast

The market is moving from routine cataract and correction products towards premium lenses, connected diagnostics and myopia management, as older patients seek spectacle independence and children's eye health gains attention. Vision Correction Devices remain the largest category, while Diagnostic and Monitoring Devices advance fastest. Refractive Errors hold the largest application share, with Glaucoma growing quickest as imaging and minimally invasive procedures spread. Optometry Practices and Retail Chains lead purchasing, and Ophthalmology Clinics and Day Surgeries gain share. New South Wales is the largest region and Queensland grows quickest. Insurance policy and surgeon capacity temper an otherwise steady mid-single-digit outlook.

Key Takeaways: Australia Ophthalmic Devices Market

Ageing Demand Underpins Steady Revenue

Revenue is on course to expand by about 72% across the decade, from AUD 875.00 million in 2025 to AUD 1,508.85 million in 2035 at a 5.6% CAGR. Cataract volumes, myopia management and equipment renewal make demand recurring.

Diagnostics and Day Surgery Lead Growth

Diagnostic and Monitoring Devices grow at an estimated 7.4% CAGR and Ophthalmology Clinics and Day Surgeries at an estimated 6.9% CAGR through 2035. Glaucoma advances at 7.8% as imaging and minimally invasive treatment move into routine care.

Insurance Policy Shapes Purchasing

Private health rebate changes, the Medicare cataract fee and surgeon capacity influence when and where lenses and equipment are bought. Manufacturers that pair implants with planning software and service gain influence. Premium lens uptake depends on whether patients retain hospital cover.

• Rebate bill reintroduced on 15 October 2026
• Cataract schedule fee of AUD 910.35 from July 2026
• Myopia control lens launched in March 2026

Australia Ophthalmic Devices Market Report Summary

Key Insight

Ageing, cataract demand and childhood myopia sustain steady procedure and product volumes, while imaging and premium lenses lift value per patient. Private providers lead purchasing; northern states grow fastest.

Key Trends in the Australia Ophthalmic Devices Market

The Australia ophthalmic devices market is being reshaped by private health insurance reform, indexed Medicare fees, myopia control products and pressure on public waiting lists.

October 2026 - Private Health Rebate Bill Returns to the Senate

• On 7 October 2026 a Senate committee recommended passing the bill, which removes age-based rebate loadings from 1 April 2027.
• The Senate voted 38 to 23 to remove the bill on 14 October 2026, and the Health Minister reintroduced it unchanged the next day.
• Trade press noted that members moving from Gold to Silver cover can lose cataract surgery cover.

September 2026 - Cataract Fee and Insurance Costs Draw Scrutiny

• A 1 September 2026 report put the Medicare fee for standard cataract surgery at AUD 910.35 after the 1 July 2026 update.
• The government rebate covers 75% of that fee, leaving a gap of roughly AUD 227 before any surgeon excess.
• Private Healthcare Australia projected that 200,000 people would downgrade cover, and about 67% of planned surgery occurs privately.

March 2026 - Myopia Control Contact Lenses Expand Locally

• On 2 March 2026 CooperVision said MyDay MiSight 1 day was immediately available in Australia and New Zealand.
• It was the lens maker's first Asia Pacific entry, and the company expects further phased expansion in the region.
• CooperVision says the lens slows myopia progression by about 50%, citing a three-year trial against single vision lenses.

December 2025 - Public Cataract Waits Shorten but Volumes Rise

• On 9 December 2025 the Australian Institute of Health and Welfare reported 791,000 public elective surgery admissions.
• Cataract surgery was the most common procedure, with 88,000 admissions, and half of patients were admitted within 106 days.
• Shorter waits show public hospitals clearing backlogs, while private facilities keep absorbing most planned surgery.

Key Insight

Insurance reform, indexed Medicare fees and myopia control products steer demand towards private day surgery and optometry. Patients weigh cover choices carefully, which sharpens competition on premium lenses.

Recent Market Developments in the Australia Ophthalmic Devices Market

Recent developments, presented from the most recent, show the Australia ophthalmic devices market moving through manufacturer launches, quarterly earnings, premium lens growth and optometry network expansion.

September 2026 - ZEISS Previews Cataract and Retinal Workflow Advances

• On 3 September 2026 ZEISS announced the AT Lucia toric 721P lens and the DORC EVA Nexus surgical system for ESCRS 2026.
• It also introduced a cloud-based Surgery Planner expected in select markets in autumn in the northern hemisphere, plus a VisuMax 800 software update.
• ZEISS is developing a retinal diagnostic offering to complement Cirrus OCT, and virtual reality perimetry alongside the Humphrey Field Analyzer.

August 2026 - Alcon Reports Surgical Growth on UNITY and PanOptix Pro

• On 10 August 2026 Alcon reported second-quarter surgical sales of USD 1,570 million, up 8%, with equipment and other sales up 26%.
• The UNITY platform led equipment growth and PanOptix Pro drove lens growth, while implantable sales rose 2%.
• Alcon also agreed a non-exclusive collaboration with RxSight to co-develop adjustable presbyopia-correcting lenses.

July 2026 - Bausch + Lomb Premium Lens Sales Surge

• On 29 July 2026 Bausch + Lomb reported second-quarter surgical revenue of USD 256 million, up 19%.
• Premium lenses grew 175% and now represent 13% of surgical revenue, compared with 6% in 2025.
• A pivotal study of the investigational enVista Beyond lens narrowly missed some targets, so the company will engage regulators on next steps.

October 2025 - Specsavers Reports Australian Revenue Growth and Dry Eye Pilots

• On 1 October 2025 Specsavers reported Australian revenue of GBP 863.3 million, up 8.1%, with 395 optical stores.
• The group piloted low-level light and intense pulsed light dry eye treatments, with plans to extend them across Australian and New Zealand clinics.
• Seven new stores and more than 160 refits added sight test capacity and diagnostic equipment demand.

Key Insight

Manufacturers are launching premium lenses, surgical platforms and planning software while retail optometry adds services. Premium lens growth and equipment launches stand out in the latest quarterly results.

Australia Ophthalmic Devices Industry Segmentation

The Expert Market Research’s report on the Australia Ophthalmic Devices Market offers a detailed analysis of the market based on the following segments.

Market Breakup by Device Type

• Surgical Devices
• Diagnostic and Monitoring Devices
• Vision Correction Devices
• Others

Vision Correction Devices lead revenue, as CooperVision brought MyDay MiSight 1 day to Australia in March 2026 and Specsavers reported 395 Australian optical stores in October 2025. Surgical Devices cover lenses, phacoemulsification systems, glaucoma stents and lasers, with Alcon reporting surgical sales growth in August 2026 and Lumibird reporting medical division revenue in September 2026. Diagnostic and Monitoring Devices grow fastest at an estimated 7.4% CAGR, as Optos promoted ultra-widefield imaging across Australian events in 2026. Others covers instruments, accessories and software.

Market Breakup by Application

• Refractive Errors
• Cataract
• Glaucoma
• Retinal Disorders
• Others

Refractive Errors lead revenue, supported by contact lens launches such as MyDay MiSight 1 day in March 2026. Cataract follows, with 88,000 public admissions reported in December 2025 and Bausch + Lomb premium lens sales up 175% in July 2026. Glaucoma grows fastest at an estimated 7.8% CAGR as minimally invasive stents, laser treatment and optical coherence tomography monitoring spread. Retinal Disorders benefit from widefield imaging. Others includes dry eye, where Specsavers piloted light-based treatments in October 2025.

Market Breakup by End User

• Optometry Practices and Retail Chains
• Hospitals
• Ophthalmology Clinics and Day Surgeries
• Others

Optometry Practices and Retail Chains lead purchasing, as Specsavers reported seven new stores and more than 160 refits in October 2025. Hospitals buy through state tenders and cover public lists, where half of cataract patients were admitted within 106 days in December 2025. Ophthalmology Clinics and Day Surgeries grow fastest at an estimated 6.9% CAGR, because about 67% of planned surgery happens privately and the Senate reintroduced the rebate bill in October 2026. Others covers research institutes, aged care and mobile eye services.

Market Breakup by Region

• New South Wales
• Victoria
• Queensland
• Western Australia
• South Australia
• Others

New South Wales dominates through the largest population and densest private surgical network, growing at an estimated 5.4% CAGR through 2035. Victoria follows at 5.3%, with Optos scheduled to attend Melbourne Interactive in May 2026 and OSHOW in August 2026. Queensland is the fastest-growing region at an estimated 6.5%, as the AUSCRS congress was scheduled for the Sunshine Coast in July 2026. Western Australia grows at 5.9% on population inflow. South Australia grows at 5.5%, home to the Adelaide-based Ellex laser brand of Lumibird Medical. Others covers Tasmania, the ACT and the Northern Territory at 5.6%.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Competitive Landscape in the Australia Ophthalmic Devices Market

Competition combines global lens and equipment makers with local sales and service teams, and large optometry and surgical groups that buy at scale. Barriers include regulatory registration, surgeon training, clinical evidence, service coverage and software ecosystems.

Alcon

Alcon, headquartered in Geneva, Switzerland, supplies intraocular lenses, phacoemulsification platforms, surgical consumables, contact lenses and eye care products to Australian surgeons, hospitals and optometrists through its local business. On 10 August 2026 it reported second-quarter surgical sales of USD 1,570 million, up 8%, led by the UNITY platform and PanOptix Pro lens. Alcon also announced a non-exclusive agreement with RxSight to co-develop adjustable presbyopia-correcting lenses.

Bausch + Lomb

Bausch + Lomb, headquartered in Vaughan, Ontario, Canada, supplies contact lenses, enVista intraocular lenses, surgical equipment and eye health products in Australia through Bausch + Lomb Australia. On 29 July 2026 it reported second-quarter surgical revenue of USD 256 million, up 19%, with premium lenses growing 175%. The enVista Beyond lens remains investigational, and the company is reviewing pivotal data before engaging regulators.

CooperVision

CooperVision, the contact lens business of The Cooper Companies, is headquartered in Pleasanton, California, and supplies daily and monthly lenses to Australian optometrists and retailers. On 2 March 2026 it announced that MyDay MiSight 1 day myopia control lenses were immediately available in Australia and New Zealand, its first Asia Pacific entry. The company says the lens slows myopia progression by about 50%, citing a three-year trial.

ZEISS

ZEISS Medical Technology, part of Carl Zeiss Meditec AG headquartered in Jena, Germany, sells Cirrus OCT scanners, Humphrey perimeters, surgical microscopes and intraocular lenses to Australian clinics through a local subsidiary. On 3 September 2026 it announced the AT Lucia toric 721P lens, the DORC EVA Nexus surgical system and a cloud-based Surgery Planner. Australian availability of the new products has not been confirmed.

Other players operating in the Australia ophthalmic devices market include Johnson & Johnson Vision, Topcon Healthcare, Optos, Lumibird Medical, and Glaukos, alongside regional distributors, laser and microscope service providers, spectacle and contact lens suppliers and imaging software vendors supplying clinics and hospitals across Australia.

Key Insight

Competition rests on clinical evidence, surgeon training, service coverage and software ecosystems rather than price alone. Global manufacturers hold scale, while large optometry groups negotiate network-wide supply agreements.